One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Spero Therapeutics logo
Spero Therapeutics SPRO
$ 0.74 -9.76%
report update icon

Quarterly report 2026-Q3
added 11-12-2026

Spero Therapeutics Financial Ratios 2025-2011 | SPRO

Brief overview of Spero Therapeutics's financial ratios

The review covers five available annual periods spanning 2021 to 2025.

Key multiples at the end of the period are EV/EBITDA 16.22x (median 2.65x), P/S 1.99x (median 1.99x), P/B 2.25x (median 2.25x). The combined ratio level is close to the company's five-year norm at a 0% deviation. No clear premium or discount is visible.

Capital efficiency is characterized by ROE 14.5%, ROA 12.4%, ROCE 10.7%. Capital returns look adequate and support overall financial resilience.

Overall picture

Spero Therapeutics trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.

Annual Financial Ratios Spero Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
15.5 -1.9 3.8 -1.1 -4.1 -4.2 -2.9 -3.7 -0.8 - -4.9 - - - -

P/S

2.0 2.7 0.8 1.0 20.1 35.3 9.7 38.4 16.2 - - - - - -

EPS

0.1 -1.3 0.4 -1.2 -2.9 -3.5 -3.4 -2.6 -17.8 -95.9 -53.1 - - - -

EV (Enterprise Value)

102 M 140 M 86.7 M -7.24 M 337 M 265 M 178 M 131 M -46.7 M 7.41 M 56.9 M - - - -

EBITDA per Share

0.11 -1.36 0.41 -1.1 -2.83 -4.31 -3.44 -2.65 -16 - -0.971 - - - -

EV/EBITDA

16.2 -1.9 4.0 0.2 -3.9 -3.1 -2.3 -2.8 1.3 - -4.4 - - - -

PEG

-0.1 0.01 -0.11 0.05 - 0.15 0.1 -0.04 0.01 - 1.63 - - - -

P/B

2.2 2.8 0.8 0.7 4.2 2.5 2.4 1.3 0.4 - 252.4 - - - -

P/CF

-10.5 -5.5 -2.7 -6.9 -5.7 -3.8 -3.5 -3.6 -0.8 - -5.0 - - - -

ROE %

14.52 -148.66 21.34 -61.13 -101.71 -59.29 -81.70 -36.07 -45.79 - -5180.61 - - - -

ROA %

12.44 -62.03 12.50 -37.19 -52.49 -51.01 -57.42 -32.29 -41.45 - -141.50 - - - -

ROCE %

10.51 -119.35 14.79 -40.91 -57.72 -56.87 -79.58 -36.68 -48.91 - -1742.12 - - - -

Current Ratio

7.0 1.7 2.4 2.6 2.1 9.7 3.6 10.1 11.3 - 0.9 - - - -

DSO

- - - - - 241.6 171.9 119.5 542.8 - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Spero Therapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.76 -0.16 -0.13 0.5599999999999999 -0.13 -0.03 -0.25 -0.38 -0.32 -0.33 -0.24 0.97 -0.06 -0.23 -0.25 0.9300000000000002 -0.33 -0.87 -1.01 -0.9200000000000002 -0.7 -0.63 -0.66 -0.6099999999999999 -0.86 -0.85 -1.22 -1.31 -0.95 -0.74 -0.29 -0.6 -0.6 -0.69 -0.74 -1.59 -36.02 -36.21 -21.6 -25.68 -23.23 -25.3 -21.51 - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.72 -0.17 -0.13 204 -0.14 -0.04 -0.27 -129 -0.34 -0.35 -0.26 507 -0.03 -0.24 -0.27 6.95 -0.32 -0.78 -0.92 -57.1 -0.7 -0.62 -0.65 -11.1 -0.86 -0.88 -1.16 -1.36 -0.94 -0.76 -0.32 -0.62 -0.62 -0.69 -0.75 -1.5 -28.9 -29.9 -22.8 - -24.2 - - - - - - - - - - - - - - - - - - - - - -

ROE %

-5651.21 -9.67 6.76 -20.64 -119.34 -117.65 -134.66 -106.81 -13.64 6.57 7.01 -0.29 109.33 79.36 21.26 -10.83 -201.45 -185.64 -126.37 -90.17 -71.12 -65.26 -68.42 -69.72 -89.15 -93.94 -82.19 -69.01 -44.66 -33.95 -37.12 -46.85 -55.09 -32.00 -62.58 -94.12 -60.86 -61.72 -45.74 15.87 13.90 - - - - - - - - - - - - - - - - - - - - - -

ROA %

-24.82 1.80 17.17 11.53 -53.10 -52.16 -61.34 -51.05 -4.09 5.60 5.47 1.24 69.00 53.89 20.86 10.14 -102.79 -100.25 -70.70 -61.73 -56.75 -53.24 -55.65 -57.29 -68.73 -72.42 -65.22 -54.10 -38.77 -30.71 -33.69 -42.75 -50.33 -80.92 -108.61 -136.88 -173.43 -181.02 -41.40 -52.36 -45.86 - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-63.16 -3.71 13.50 -2.76 -90.40 -92.47 -105.57 -86.34 -16.20 3.03 5.51 0.73 -8.93 -31.08 -68.07 -91.61 -134.78 -127.93 -92.51 -68.53 -63.99 -59.95 -66.11 -67.96 -87.03 -91.85 -80.27 -67.81 -44.73 -34.96 -38.12 -47.68 -54.59 -33.66 -30.56 -25.17 8.66 -12.02 -8.98 - 17.42 - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.0 6.2 9.7 7.0 2.0 2.1 1.8 1.7 1.9 2.2 2.4 2.4 2.0 2.2 2.4 2.5 2.0 2.3 1.8 2.1 4.4 4.1 5.8 7.2 6.5 4.1 7.2 3.4 5.8 9.6 11.0 9.8 12.9 10.5 13.2 11.0 4.3 11.0 11.0 1.9 1.9 - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Spero Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 22.14 -1.6 % $ 248 M usaUSA